SB 1812
once-a-year prior authorization for neurodegenerative disease drugs
Died in committee
Verdict: No flags
Initial review · graded Oct 20, 2026 · Headline, summary and grade are analysis of the bill text, not a finding about any person · How we grade
Caption
relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.
Caption from analyzed text · version I.
Summary
Neurodegenerative diseases join the short list.
The bill adds neurodegenerative diseases to the short list of conditions for which a health plan can require prior authorization for a prescription drug only once a year. It touches health insurers that offer prescription drug coverage and patients being treated for neurodegenerative diseases. Starting with plans issued or renewed on or after January 1, 2026, those patients face at most one yearly approval step for their drugs instead of repeated ones.
Labels
Labels: NEVER GOT A HEARING. Filed Mar 3, 2025 and referred to the Senate Health & Human Services committee. No public hearing. The bill died.
Receipt
The receipt
89R-SB1812 · 2025-03-03
SOLD BY
ITEM
relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases.
WHAT IT DOES
Neurodegenerative diseases join the short list.
The bill adds neurodegenerative diseases to the short list of conditions for which a health plan can require prior authorization for a prescription drug only once a year. It touches health insurers that offer prescription drug coverage and patients being treated for neurodegenerative diseases. Starting with plans issued or renewed on or after January 1, 2026, those patients face at most one yearly approval step for their drugs instead of repeated ones.
CHARGES
[ ] NONE FOUND
TOTAL
No fiscal note in the loaded record.
HISTORY
- Received by the Secretary of the Senate
- Filed
- Read first time
- Referred to Health & Human Services
FILED UNDER
No verified beat found.
THANK YOU FOR CHECKING THE RECEIPT
CAMPAIGN PAID FOR BY
CAMPAIGN PAID FOR BY
Donors
Donors report through Friends of Donna Campbell.
Not tied to this bill.
Sources
The author's campaign account only. Own money and internal transfers are separate on the member page.
Derived itemized flow · Oct 27, 2024 to Jun 30, 2026. State data as of Nov 4, 2026.
Derived itemized contributions on live regular reports and uncovered special-session dates. Internal account transfers and daily reports are excluded.
MoneyMissing data does not establish zero giving. Display amounts are rounded.
Votes
No floor vote loaded for this bill.
Fiscal
No fiscal note in the loaded record.
How this was graded
Analysis of text version I by claude-opus-5-5, Oct 20, 2026, against the published rubric.
Sources
Texas Senate · Filed Mar 3, 2025
03/13/2025 S Referred to Health & Human Services
Texas Legislature Online · Introduced
Data snapshot Oct 26, 2026 at 4:20 AM CDT. Grades, charges, quotes and corrections follow the published record.
Senate committee · Health & Human Services · Final status: Died in committee
Subjects
Health--Other Diseases & Medical Conditions
Insurance--Health & Accident
MEDICINE & PRESCRIPTION DRUGS
Text
The text as introduced · 215 words
89R12618 DNC-D By: Campbell, Menéndez S.B. No. 1812 A BILL TO BE ENTITLED AN ACT relating to prior authorization for prescription drug benefits related to the treatment of neurodegenerative diseases. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: SECTION 1. The heading to Subchapter N, Chapter 1369, Insurance Code, is amended to read as follows: SUBCHAPTER N. COVERAGE OF PRESCRIPTION DRUGS FOR CERTAIN [ AUTOIMMUNE ] DISEASES AND [ CERTAIN BLOOD ] DISORDERS SECTION 2. Section 1369.654(a), Insurance Code, is amended to read as follows: (a) A health benefit plan issuer that provides prescription drug benefits may not require an enrollee to receive more than one prior authorization annually of the prescription drug benefit for a prescription drug prescribed to treat an autoimmune disease, hemophilia, a neurodegenerative disease, or Von Willebrand disease. SECTION 3. The change in law made by this Act applies only to a health benefit plan that is delivered, issued for delivery, or renewed on or after January 1, 2026. A health benefit plan delivered, issued for delivery, or renewed before January 1, 2026, is governed by the law as it existed immediately before the effective date of this Act, and that law is continued in effect for that purpose. SECTION 4. This Act takes effect September 1, 2025.